CLDX News and Press, Celldex Therapeutics Inc. From 10/13/25

2025-10-13 14:35:33 ET Shares of mast cell therapy concern Celldex Therapeutics, Inc. ( CLDX ) have rallied just over 70% off their 60-month April 2025 low that was caused by high discontinuation rates for lead asset barzolvolimab. The company’s only significant candidate has...

HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data demonstrating rapid and strong efficacy regardless of baseline immunoglobulin E (IgE) levels in patients with chronic spontaneous urticaria (CSU), an immune-related condition driven by mast cell a...

2025-09-10 12:20:09 ET Celldex Therapeutics, Inc. (CLDX) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 3:20 PM EDT... Read the full article on Seeking Alpha For further details see: Celldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd...

HAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanley 23rd Annual Global Healthcare Conference at 3:20 pm ET. A live webcast of the presentatio...

Celldex Therapeutics Inc. (CLDX) is expected to report $-0.86 for Q2 2025

2025-08-07 17:42:50 ET More on Celldex Biggest stock movers Friday: Crypto-linked stocks, ADBE, V, MA, and more Seeking Alpha’s Quant Rating on Celldex Historical earnings data for Celldex Financial information for Celldex Read the full artic...

Strong execution and continued progress across pipeline Unprecedented data delivered from Phase 2 CSU study demonstrating profound, sustained complete response and improved quality of life 7 months after completion of barzolvolimab dosing Data anticipated from Phase 2 studies of b...

77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52 Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:C...

2025-06-13 11:13:32 ET More on related stocks: RH (RH) Q1 2025 Earnings Call Transcript Adobe Inc. (ADBE) Q2 2025 Earnings Call Transcript Adobe Inc. 2025 Q2 - Results - Earnings Call Presentation Bitcoin tumbles as Israel strikes Iran RH maintains 10...

Seven months after the completion of dosing: 41% of patients (150 mg Q4W) continue to experience complete response (UAS7=0) 48% of patients (150 mg Q4W) report that CSU no longer impacts their quality of life (DLQI=0/1) KIT related tolerability events demonstrated to be reversible ...